Cannabis and glaucoma have a history that goes back to the 1970s, when NASA-funded research first documented that smoking cannabis lowered intraocular pressure. Fifty years later, the story is more complicated than that finding suggested.
How Glaucoma Damages Vision
Glaucoma is a group of conditions characterized by progressive optic nerve damage, most commonly associated with elevated intraocular pressure. IOP above approximately 21 mmHg is a primary risk factor, though some glaucoma occurs at normal pressures (normal-tension glaucoma). Untreated glaucoma is one of the leading causes of blindness globally.
Lowering IOP is the primary treatment goal for most glaucoma. Standard approaches include eye drops (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors), laser procedures, and surgery. These approaches provide sustained IOP reduction over 24 hours with controlled, predictable dosing.
The Original Cannabis-IOP Research
In 1971, researchers Hepler and Frank published a landmark finding in JAMA: smoking cannabis significantly reduced IOP in healthy individuals. This was replicated across multiple subsequent studies. By the mid-1970s, several glaucoma patients were using cannabis medically, and the condition became one of the first qualifying conditions when state medical cannabis programs began emerging in the 1990s.
The mechanism appears to involve CB1 receptors in the ciliary body, the eye tissue responsible for aqueous humor production. THC activation of these receptors reduces aqueous humor production and/or increases outflow, lowering IOP. This effect is documented in both smoked cannabis and THC administered through other routes.
The Duration Problem
The core clinical limitation of cannabis as a glaucoma treatment is that the IOP-lowering effect lasts approximately 3-4 hours per dose. Glaucoma requires sustained 24-hour IOP control. Achieving this with cannabis would require 6-8 doses of cannabis per day around the clock, including through the night, without tolerance developing.
The American Academy of Ophthalmology’s position paper specifically notes this limitation: the short duration of action, the potential for tolerance with frequent use, and the psychoactive and cognitive effects of the required dosing frequency make cannabis impractical as a glaucoma treatment compared to available alternatives that provide sustained IOP control with a single daily dose.
The CBD Warning for Glaucoma Patients
A 2018 study published in Investigative Ophthalmology and Visual Science found that CBD — unlike THC — transiently increased IOP in mice by 18% for four hours. A 2024 survey study found that some human glaucoma patients using CBD products reported IOP increases. The mechanism may involve CBD acting as a CB1 receptor antagonist, partially blocking the IOP-lowering effects of the endocannabinoid system.
This finding is clinically important: glaucoma patients using CBD products, including CBD gummies, oils, or topicals marketed for relaxation or wellness, may unknowingly be worsening their IOP. The American Glaucoma Society has issued a statement advising glaucoma patients to discuss any cannabis or CBD use with their ophthalmologist.
Research on Cannabinoid Eye Drops
Several research groups are attempting to develop topical cannabinoid formulations that could deliver IOP-lowering effects directly to the eye without systemic psychoactive effects and with longer duration of action. Challenges include cannabinoids’ poor water solubility and difficulty penetrating the cornea.
As of 2026, no cannabinoid eye drop has completed the clinical trial process required for FDA approval as a glaucoma treatment. Research is ongoing, and this is considered an active area of investigation rather than a dead end.
What Ophthalmologists Recommend
Ophthalmologists managing glaucoma patients are consistent in their guidance: cannabis should not replace or delay evidence-based glaucoma treatment. A single missed prostaglandin analog eye drop can result in IOP spikes that cause optic nerve damage. Cannabis’s short duration of action and dosing impracticality make it an unreliable substitute.
Ophthalmologists in legal cannabis states commonly ask patients to disclose any cannabis use, partly to assess whether CBD-containing products might be affecting IOP readings. Full disclosure allows for an informed clinical picture.
This article is for informational purposes only and is not medical advice. Glaucoma requires professional diagnosis and treatment. Do not change your glaucoma treatment plan without consulting your ophthalmologist.
Frequently Asked Questions
Does smoking cannabis help glaucoma?
Smoking cannabis does temporarily lower intraocular pressure, which is documented in research since the 1970s. The problem is that the effect only lasts 3-4 hours, requiring around-the-clock dosing to maintain therapeutic IOP levels. Ophthalmology organizations do not recommend cannabis as a glaucoma treatment for this reason.
Is CBD safe for people with glaucoma?
Research suggests CBD may actually increase intraocular pressure in some individuals, which is the opposite of the desired effect in glaucoma. Glaucoma patients should discuss any cannabis or CBD product use with their ophthalmologist before starting.
